Is signal peptide-CUB-EGF domain-containing protein1 a diagnostic biomarker in patients with hypertensive crises

Abstract

BACKGROUND:

Platelet activation might play a significant role in the pathophysiology of cardiovascular and cerebrovascular events in hypertension (HT). Signal peptide-CUB-EGF domain-containing protein1 (SCUBE1), an indicator of platelet activation, is increased in HT. The aim of this study was to investigate the SCUBE1 in patients with hypertensive crises.

METHODS:

This study included 33 hypertensive urgency (HU) and 39 hypertensive emergency (HI) patients admitted to our emergency department with a diagnosis of hypertensive crisis. Platelet activation was evaluated with biochemical markers such as SCUBE1, soluble CD40L (sCD40L), mean platelet volume, and platelet count.

RESULTS:

The SCUBE1 values of the HE patients were significantly higher than other groups (1.09 ± 0.49, 0.71 ± 0.23 and 0.37 ± 0.02 ng/dl, respectively; p < 0.01). The sCD40L values were higher in the hypertensive crises compared with the control group (4.16 ± 1.82, 3.41 ± 1.76 and 1.76 ± 0.68 ng/ml, respectively; p < 0.01). More importantly, SCUBE1 had high sensitivity and specificity in the detection of target organ damage.

CONCLUSION:

In present study showed that SCUBE1 was significantly higher in HE patients. In addition, sCD40L level, presence of diabetes, and systolic blood pressure were independently associated with increased SCUBE1. According to our results, SCUBE1 might be a diagnostic biomarker in hypertensive crisis patients.

Keywords

Hypertensive crises signal peptide-CUB-EGF domain-containing protein1 target organ damage soluble CD40 ligand mean platelet volume

Get full access to this article

View all access options for this article.

References

Ault

M.J.

and Ellrodt

A.G.

, Pathophysiological events leading to the end-organ effects of acute hypertension, Am J Emerg Med 3 (1985), 10–15.

Bath

, Algert

, Chapman

and Neal

, Progress Collaborative Group. Association of mean platelet volume with risk of stroke among individuals with history of cerebrovascular disease, Stroke 35 (2004), 622–626.

Blann

A.D.

, Nadar

and Lip

G.Y.

, Pharmacological modulation of platelet function in hypertension, Hypertension 42 (2003), 1–7.

Bulur

, Onder

H.I.

, Aslantas

, Ekinozu

, Kilic

A.C.

, Yalcin

, Bulur

and Ozhan

, Relation between indices of end-organ damage and mean platelet volume in hypertensive patients, Blood Coagul Fibrinolysis 23 (2012), 367–369.

Dai

D.F.

, Thajeb

, Tu

C.F.

, Chiang

F.T.

, Chen

C.H.

, Yang

R.B.

, etal., Plasma concentration of SCUBE1, a novel platelet protein, is elevated in patients with acute coronary syndrome and ischemic stroke, J Am Coll Cardiol 51 (2008), 2173–2180.

El Haouari

and Rosado

J.A.

, Platelet function in hypertension, Blood Cells Mol Dis 42 (2009), 38–43.

Erdogan

, Icli

, Aksoy

, Akcay

, Ozaydin

, Ersoy

, Varol

and Dogan

, Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure, Chronobiol Int 30 (2013), 973–980.

Ferroni

, Guagnano

M.T.

, Falco

, Paoletti

, Manigrasso

M.R.

, Michetti

, Santilli

, Guadagni

, Basili

and Daví

, Association of low-grade inflammation and platelet activation in patients with hypertension with microalbuminuria, Clin Sci (Lond) 114 (2008), 449–455.

Gonzalez

, Morales

, Segura

, Ruilope

L.M.

and Praga

, Long-term renal survival in malignant hypertension, Nephrol Dial Transplant 25 (2010), 3266–3272.

10.

Henn

, Slupsky

J.R.

, Gräfe

, Anagnostopoulos

, Förster

, Müller-Berghaus

and Kroczek

R.A.

, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature 391 (1998), 591–594.

11.

Karabacak

, Dogan

, Turkdogan

A.K.

, Kapci

, Duman

and Akpinar

, Mean platelet volume is increased in patients with hypertensive crises, Platelets (2013).

12.

Mancia

, Fagard

, Narkiewicz

, Redón

, Zanchetti

, Bohm

, Christiaens

, Cifkova

, De Backer

, Dominiczak

, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), J Hypertens 31 (2013), 1281–357.

13.

Nadar

, Blann

A.D.

and Lip

G.Y.

, Platelet morphology and plasma indices of platelet activation in essential hypertension: Effects of amlodipine-based antihypertensive therapy, Ann Med 36 (2004), 552–557.

14.

Nadar

S.K.

, Blann

A.D.

, Kamath

, Beevers

D.G.

and Lip

G.Y.

, Platelet indexes in relation to target organ damage in high-risk hypertensive patients: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), J Am Coll Cardiol 44 (2004), 415–422.

15.

Novo

, Basili

, Tantillo

, Falco

, Daví

, Novo

, Corrado

and Daví

, Soluble CD40L and cardiovascular risk in asymptomatic low-grade carotid stenosis, Stroke 36 (2005), 673–675.

16.

Özkan

, Ulusoy

, Menteşe

, Karahan

S.C.

and Cansiz

, New marker of platelet activation, SCUBE1, is elevated in hypertensive patients, Am J Hypertens 26 (2013), 748–753.

17.

Punda

, Polic

, Rumboldt

, Bagatin

, Marković

and Lukin

, Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: Randomized crossover trial, Croat Med J 46 (2005), 219–224.

18.

Reinhart

W.H.

, Platelets in vascular disease, Clin Hemorheol Microcirc 53(1-2) (2013), 71–79.

19.

Tsiara

, Elisaf

, Jagroop

I.A.

and Mikhailidis

D.P.

, Platelets as predictors of vascular risk: Is there a practical index of platelet activity?, Clin Appl Thromb Hemost 9 (2003), 177–190.

20.

C.F.

, Su

Y.H.

, Huang

Y.N.

, Tsai

M.H.

, Li

L.T.

, Chen

Y.L.

, et al., Localization and characterization of a novel secreted protein SCUBE1 in human platelets, Cardiovasc Res 71 (2006), 486–495.

21.

Van den Born

B.J.

, Beutler

J.J.

and Gaillard

C.A.

, Dutch guideline for the management of hypertensive crisis – revision, Neth J Med 69 (2011), 248–255.

22.

Van den Born

B.J.

, Koopmans

R.P.

, Groeneveld

J.O.

and van Montfrans

G.A.

, Ethnic disparities in the incidence, presentation and complications of malignant hypertension, J Hypertens 24 (2006), 2299–2304.

23.

Wallach

, Karp

R.B.

, Reves

J.G.

, Oparil

, Smith

L.R.

and James

T.N.

, Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: A study of hemodynamic and humoral factors, Am J Cardiol 46 (1980), 559–565.

24.

Yang

R.B.

, Ng

C.K.

, Wasserman

S.M.

, Colman

S.D.

, Shenoy

, Mehraban

, et al., Identification of a novel family of cell-surface proteins expressed in human vascular endothelium, J Biol Chem 277 (2002), 46364–46373.

25.

Yarlioglues

, Kaya

M.G.

, Ardic

, Dogdu

, Kasapkara

H.A.

, Gunturk

, Akpek

, Kalay

, Dogan

, Ozdogru

, et al., Relationship between mean platelet volume levels and subclinical target organ damage in newly diagnosed hypertensive patients, Blood Press 20 (2011), 92–97.